|Day Low/High||84.51 / 88.23|
|52 Wk Low/High||80.85 / 153.15|
Incyte Corporation (Nasdaq:INCY) announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.
Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of Incyte's common stock at a price of $88.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #79 spot from Fidelity National Information Services Inc , according to ETF Channel. Below is a chart of Incyte Corporation versus Fidelity National Information Services Inc plotting their respective rank within the S&P 500 over time (INCY plotted in blue; FIS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 36 th Annual J.
The most recent short interest data has been released for the 11/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year) follow-up data from the ongoing, global, multi-center, open-label Phase 3 RESPONSE study of Jakafi ® (ruxolitinib) comparing the efficacy and...
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVH, FBIZ, FLWS, NWSA, RPM Downgrades: EQS, FRAN, FUNC, GVP, INCY, MPAA, OXBR, PCTY, SNFCA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi ®) compared to anagrelide for the treatment of patients with essential...
Jim Cramer highlights Apache, Incyte, Prudential, and ON Semiconductor in the Lightning Round.
Jim Cramer says the playing field is all digital, and companies need the best technology when competitors like Amazon are both enemy and ally at the same time.
- Post-hoc analysis presented at ACR/ARHP shows pain improvement was consistent regardless of a patient's baseline pain severity
Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts including data from its clinical development programs for Jakafi ® (ruxolitinib), JAK1, PI3Kd, PIM and BRD will be presented at the upcoming...
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
Incyte Corporation (Nasdaq: INCY) today reports 2017 third-quarter financial results, highlighting 38 percent year-on-year growth in product-related revenue, driven by increased sales of Jakafi ® (ruxolitinib) in the U.
Incyte Corporation (Nasdaq:INCY) and MedImmune, AstraZeneca's (NYSE:AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration.
Incyte Corporation (Nasdaq:INCY) today announced the appointment of Jacqualyn "Jackie" A.
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational...
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 26 th Annual Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 9:45am (MST) in Scottsdale, Arizona.
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.
Incyte Corporation (Nasdaq:INCY) and Cancer Support Community Delaware (CSCDE) today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for...
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte's...
The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.